Results 121 to 130 of about 6,115 (159)

Ulcerative colitis and bullous pemphigoid: Direct association or a medication side effect: A case report.

World J Clin Cases
Haddad GC, El Dada A, Sbeih S, Kazzi T, Karam K, Chaptini LA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mesalamine

Hospital Pharmacy, 2007
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Danial E. Baker, Terri Levien   +2 more
openaire   +1 more source

Mesalamine-Associated Thrombocytopenia

American Journal of Gastroenterology, 1999
We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine. In contrast to its parent drug, sulfasalazine, which has often been reported to cause serious blood disorders, particularly agranulocytosis, mesalamine has rately been implicated as a cause of
R J, Farrell, M A, Peppercorn, S N, Fine, P, Michetti   +3 more
openaire   +3 more sources

Asacol (Mesalamine)

Gastroenterology Nursing, 1992
Asacol (mesalamine) is a delayed release pH-sensitive, polymer-coated, oral preparation of 5-ASA which releases the drug in the terminal ileum and colon for the treatment of mildly to moderately active ulcerative colitis. Treatment modalities using Asacol appear to be an alternative for sulfasalazine-sensitive patients as well as potential first-line ...
openaire   +2 more sources

Pentasa (Mesalamine)

Gastroenterology Nursing, 1993
Pentasa (mesalamine) is a newly released oral 5-aminosalicylic acid capsule marketed by Marion Merrel Dow Inc., for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis. Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and ...
openaire   +2 more sources

Mesalamine-Induced Granulomatous Hepatitis

American Journal of Gastroenterology, 1999
A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests. Endoscopic retrograde cholangiopancreatography demonstrated a normal biliary tree, and liver biopsy showed granulomata.
M, Braun, G M, Fraser, M, Kunin, F, Salamon, R, Tur-Kaspa   +4 more
openaire   +2 more sources

Mesalamine in Ulcerative Colitis

DICP, 1991
Sulfasalazine has been used for many years in the management of ulcerative colitis. As many as 20 percent of patients treated with it experience intolerable adverse effects usually attributed to its sulfapyridine component. The other active component is 5-aminosalicylic acid (5-ASA); the only 5-ASA enema preparation currently available in the U.S.
J M, Fitzgerald, T D, Marsh
openaire   +2 more sources

Mesalamine-induced eosinophilic pleural effusion

BMJ Case Reports, 2020
A 45-year-old woman with a medical history of ulcerative colitis (UC) presented with difficulty in breathing. The patient was diagnosed with UC a month prior to presentation and was started on mesalamine suppository. Chest x-ray (CXR) on presentation showed bilateral pleural effusion, which was confirmed on CT angiogram of the chest.
Abdullah Al-abcha, Fazal Raziq, Shouq Kherallah, Ahmad Alratroot   +3 more
openaire   +2 more sources

Rowasa Suspension Enema (Mesalamine, USP)

Gastroenterology Nursing, 1989
Rowasa (mesalamine) rectal suspension enema, a new product by Reid-Rowell, represents a major breakthrough in the treatment of distal ulcerative colitis. It provides patients with an alternative therapy to the current oral and enema preparations. This treatment reduces the incidence of unwanted side effects and toxicity associated with oral therapy.
CECELIA A. CIARLEGLIO, Melanie L. Swartz
openaire   +2 more sources

MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations

Digestive and Liver Disease
Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico, Francesca, Lusetti, Laurent, Peyrin-Biroulet, Silvio, Danese   +3 more
openaire   +2 more sources